Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03153982 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib in Operable Head and Neck Cancer
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT03153982 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 16 participants.
The verdict
NCT03153982, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of ruxolitinib in patients with operable Head and neck squamous cell carcinoma (HNSCC) who are planned for definitive surgery.
Interventions
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-06-08 |
| Est. Completion | 2023-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03153982
The ClinicalTrials.gov registry entry for NCT03153982 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT03153982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03153982 about?
NCT03153982 is a clinical study titled "Ruxolitinib in Operable Head and Neck Cancer". The purpose of this study is to assess the safety and efficacy of ruxolitinib in patients with operable Head and neck squamous cell carcinoma (HNSCC) who are planned for definitive surgery.
What is the current status of trial NCT03153982?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2018-06-08. Estimated completion is 2023-10-18.
What interventions are being tested in trial NCT03153982?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT03153982?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.